Dupixent® (Dupilumab) Approved By FDA As The First And Only …

(MENAFN- PR Newswire)

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials

About 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options

Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S.

TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: ) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with…



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.